VIR - Vir Biotechnology, Inc.
IEX Last Trade
7.4
0.020 0.270%
Share volume: 64,939
Last Updated: Thu 26 Dec 2024 08:30:05 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$7.38
0.02
0.27%
Fundamental analysis
15%
Profitability
18%
Dept financing
5%
Liquidity
75%
Performance
0%
Performance
5 Days
0.54%
1 Month
-3.15%
3 Months
1.10%
6 Months
-18.90%
1 Year
-27.58%
2 Year
-70.60%
Key data
Stock price
$7.40
DAY RANGE
$7.17 - $7.42
52 WEEK RANGE
$7.00 - $13.05
52 WEEK CHANGE
-$28.28
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: George A. Scangos
Region: US
Website: vir.bio
Employees: 580
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vir.bio
Employees: 580
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs, for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health.
Recent news